ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors

Sponsor: Adagene Inc

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05405595

Patient View

This Phase 1b/2 open-label study assesses the safety, tolerability, PK, and preliminary efficacy of ADG126, an anti-CTLA-4 antibody, combined with Pembrolizumab in advanced/metastatic solid tumors. Eligible patients are adults with ECOG 0-1, measurable lesions, and adequate organ function. The combination is administered until disease progression or intolerable toxicity.

Patient Parameters

Program Overview

This is a Phase 1b/2, open-label, dose escalation study to evaluate the safety, tolerability, PK, and immunogenicity of ADG126-pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.

Description

This is a Phase 1b/2, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of ADG126-Pembrolizumab combination regimens in patients with advanced/metastatic solid tumors.

Study drug ADG126 is an anti-CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. Pembrolizumab is a PD-1 receptor-blocking antibody (a humanized IgG4 monoclonal antibody).

Eligibility Criteria

Inclusion Criteria

  1. ≥18 years of age at the time of informed consent.

  2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

  3. Wash out period from previous antitumor therapies

  4. At least 1 measurable lesion at baseline according to the definition of RECIST v1.1.

  5. Adequate organ function.

  6. An archival tumor biopsy is required and should be taken within 2 years of enrollment. If not available, a fresh tumor biopsy is acceptable.

  7. For Dose Escalation Phase Only: Patients with advanced or metastatic solid tumors, histologically or pathologically confirmed, who have progressed after all standard therapies, or for whom no further standard therapy exists.

    Dose Expansion Phase Only: Tumor tissues (archived or fresh biopsy) before treatment are required for all patients. Biopsies and tumor tissues after treatment are optional but preferred for patients with MSS-CRC and 2L anti-PD-1/anti-PD-L1 experienced NSCLC.

  8. No prior immunotherapy

Exclusion Criteria

  1. Pregnant or breastfeeding females.
  2. Childbearing potential who does not agree to the use of contraception during the treatment period.
  3. Treatment with any investigational drug within washout period.
  4. Prior treatment with an anti-CTLA-4 therapy.
  5. History of significant immune-mediated AE.
  6. Central nervous system (CNS) disease involvement.
  7. History or risk of autoimmune disease.
  8. Patients requiring systemic treatment with corticosteroids or other immunosuppressive medications (>10 mg/day prednisone or equivalent).
  9. Any uncontrolled active infections requiring systemic antimicrobial treatment (viral, bacterial, or other), or uncontrolled or poorly controlled, asthma, chronic obstructive pulmonary disease (COPD).
  10. Major surgery within 4 weeks prior to the first dose of the study drug.
  11. Has had an allogeneic tissue/solid organ transplant.
  12. Has received a COVID-19 vaccine within 7 days prior to the first dose of study treatment. Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study treatment. Note: Administration of killed vaccines are allowed.
  13. A positive COVID-19 test within 14 days of Cycle 1 Day 1.

Get This Program In Your Inbox

You can sign up and apply your patients for this program.